Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.54 |
| ▸ | CTSK | P43235 | 4/20 | 0.54 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.42 |
| ▸ | AKT1 | P31749 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4282127 | 0.89 | CTSS (0.54) | CTSSCTSKCTSLCTSBPSEN1 | |
| SCHEMBL4972546 | 0.88 | ITGA4 (0.48) | CTSSCTSKCTSLCTSBPSEN1 | |
| SCHEMBL4972543 | 0.88 | ITGA4 (0.48) | CTSSCTSKCTSLCTSBPSEN1 | |
| SCHEMBL4291806 | 0.88 | CTSS (0.52) | CTSSCTSKCTSLCTSBPSEN1 | |
| SCHEMBL4294527 | 0.88 | SCN9A (0.46) | CTSSCTSKCTSLCTSBPSEN1 | |
| SCHEMBL7731324 | 0.87 | CTSK (0.54) | CTSSCTSKCTSLCTSBPSEN1 | |
| SCHEMBL4283180 | 0.87 | CTSS (0.47) | CTSSCTSKCTSLCTSBPSEN1 | |
| SCHEMBL26869285 | 0.86 | CTSS (0.49) | CTSSCTSKCTSLCTSBPSEN1 | |
| SCHEMBL25403058 | 0.86 | CTSS (0.56) | CTSSCTSKCTSLCTSBPSEN1 | |
| SCHEMBL13705277 | 0.86 | CTSS (0.53) | CTSSCTSKCTSLCTSBPSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CTSS 1321/4885CTSK 979/4885CTSL 541/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CTSS 1321/4885CTSK 979/4885CTSL 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.